Food and Drug Law Journal 2024 Symposium From Past to Progress: Anticipating the Future of FDA Law and Regulation

The Food and Drug Law Institute (FDLI) is pleased to solicit abstracts for publication Journal of Food and Drug Law 2024 Symposium “From Past to Progress: Anticipating the Future of FDA Law and Regulation.” The symposium will celebrate the 75th anniversary of FDLI and its lasting contributions to the field of food and drug law by examining the future of FDA regulation while reflecting on its historical foundations.

The FDA is responsible for protecting public health by regulating foods, drugs, biologics, medical devices, tobacco, cosmetics, and more. As we look ahead to the next era of food and drug law, it is critical to consider how FDA rules and regulations will adapt to emerging technologies, evolving public health challenges, and evolving public expectations.

FDLI invites researchers, practitioners, policy makers and interested parties to submit abstracts of articles covering, among others, topics such as:

• Historical Perspectives: Reflect on the evolution of food and drug law over the past 75 years, highlighting key milestones, challenges and successes.
• Global Perspectives: Discuss the status and future of international cooperation and regulatory frameworks impacting FDA-regulated industries, including harmonization efforts and trade agreements.
• Innovation and Compliance: Learn how FDA regulations can keep pace with novel, rapidly changing and increasingly complex technologies such as artificial intelligence, personalized medicine, digital health technologies and novel food products.
• Ethical considerations: Ethical dilemmas related to food and drug regulation need to be addressed, such as access to essential medicines, patient rights, and transparency in decision-making.

The call for abstracts will end on July 8, 2024, and the authors of selected articles will be notified by July 19, 2024. The authors will submit a draft for discussion at the Symposium, which will be held on November 13, 2024 in Washington, DC. will be included in the publication in the next issue of “Gazeta”. Journal of Food and Drug Law.

FDLI invites interested authors to submit an abstract of a research law article that outlines the topics, arguments, and themes of the proposed article.

Guidelines

• Summaries should not exceed 500 words.
• All entries must be submitted via the submission portal.
• Multiple entries from a single applicant and/or organization may be accepted.
• If accepted, authors must prepare to submit the final draft of the article by October 21, 2024 and participate in a discussion of the article at the Washington Symposium on November 13, 2024.

Application submission schedule
Monday, July 8, 2024 | The recruitment of abstracts has ended
Friday, July 19, 2024 | Accepted authors will be notified
Monday, October 21, 2024 | Draft documents must be submitted
Wednesday, November 13, 2024 | FDLJ Symposium in Washington

The Journal of Food and Drug Law (FDLJ) is the publication sponsor of this Symposium and reserves the right of first refusal to publish accepted papers, subject to the editorial review process. All final submissions should be less than 25,000 words, double-spaced, and typed in Times New Roman font. FDLJ requires footnotes consistent with 21^street edition of The Bluebook: uniform citation system. Additional guidelines for authors are available Here. Questions regarding application requirements may be directed (email protected).

Please contact Paige Samson if you have any questions about the FDLJ Symposium.

Brygida BondocMorrison & Foerster LLP.
Michelle DivelbissCovington & Burling LLP
Bridget C. E. DoolingMoritz College of Law at The Ohio State University
William M. JanssenCharleston School of Law
John F. Johnson IIIShook, Hardy & Bacon LLP
Markham C. LukeFDA-CDER
Cynthia L. MeyerKleinfeld, Kaplan & Becker, LLP
Adam MuchmorePenn State Law
Daniel OrrWomble Bond Dickinson (USA) LLP
Shy ShoerNIH, NCI, CCR
Eric SoloweyParexel International Corporation
Andrzej WassonHaug Partners LLP